Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

被引：13

作者：

Du, Juan ^{[1
]}

Qiang, Wanting ^{[1
]}

Lu, Jing ^{[1
]}

Jia, Yanchun ^{[1
]}

He, Haiyan ^{[1
]}

Liu, Jin ^{[1
]}

Guo, Pei ^{[1
]}

Yang, Ying ^{[1
]}

Feng, Zhongyuan ^{[1
]}

Jin, Lina ^{[1
]}

Fan, Xiaoqiang ^{[1
]}

Liu, Jia ^{[2
]}

Zhang, Qi ^{[3
]}

Shen, Lianjun ^{[2
]}

Weng, Lihong ^{[2
]}

Li, Wenling ^{[2
]}

Cao, Wei ^{[2
]}

机构：

[1] Shanghai Changzheng Hosp, Dept Hematol, Myeloma Lymphoma Ctr, Shanghai, Peoples R China

[2] Gracell Biotechnol Ltd, Shanghai, Peoples R China

[3] Gracell Biotechnol Ltd, Shanghai, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2023-174841

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3